Selina Luger, MD, FRCPC; University of Pennsylvania #BtC_ASCO21
18:13
Dr. Selina Luger discusses Biomarkers and their Implications for Therapy in AML.
Beyond the Congress: ASCO21
Selina Luger, MD, FRCPC; University of Pennsylvania #BtC_ASCO21
Dr. Selina Luger discusses Biomarkers and their Implications for Therapy in AML.
Beyond the Congress: ASCO21 Similar Videos
Similar Videos
-
Matthew Davids, MD, MMSc; Dana-Farber Cancer Inst. #BtC_ASCO21
15:27
Dr. Matthew Davids reviews Recently Presented Data of Clinical Trials and Standard of Care in Upfront Treatment for CLL.
-
Jennifer R. Brown, MD, PhD; Dana-Farber Cancer Institute #BtC_ASCO21
15:33
Dr. Jennifer Brown reviews Recently Presented Data of Clinical Trials and Standard of Care in Relapsed/Refractory CLL.
-
Alison J. Moskowitz, MD; Memorial Sloan Kettering Cancer Center #BtC_ASCO21
16:28
Dr. Alison Moskowitz presents on Treatments for Upfront and Relapsed Hodgkin’s Lymphoma.
